HOUSTON, TX — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company concentrating on the development of novel treatments for metastatic and primary cancers in the central nervous system and the brain, today declared that as part of the annual reconstitution of the Russell stock indexes, CNS Pharmaceuticals has been chosen to be added to the Russell 2000® Index. This decision will be in effect on June 25, 2021, after the U.S. equity markets close.
The CEO of CNS Pharmaceuticals, John Climaco commented, "We are pleased to meet this noteworthy milestone and be included in the Russell 2000® Index. As our team continues to drive our clinical program forward for the treatment of glioblastoma multiforme (GBM), we believe this inclusion well-positions us to drive market awareness.
"We are honored to be listed among our industry peers on what is considered to be a widely respected performance benchmark for small-cap companies. We look forward to leveraging the access and positioning this inclusion brings to unlock additional value."
The Russell 2000® Index monitors the performance of the US equity market's small-cap division. It is a subset of the Russell 3000® Index, accounting for about 10% of the index's total market capitalization. The Russell 2000® Index contains about 2,000 of the tiniest securities depending on their market capitalization and existing index membership.
Investment managers and institutional investors utilize Russell indices for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell's U.S. indices, which are part of FTSE Russell, a global index leader that produces innovative analytics, benchmarking, as well as data solutions for investors worldwide.
For more information on the Russell Indexes, please visit the FTS Russell website at www.ftserussell.com.